

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in PuraPharm Corporation Limited, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**(I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;  
(II) PROPOSED GRANT OF GENERAL MANDATES TO BUY BACK SHARES  
AND ISSUE NEW SHARES;  
AND  
(III) NOTICE OF ANNUAL GENERAL MEETING**

---

A notice convening the annual general meeting of PuraPharm Corporation Limited (the “**Annual General Meeting**”) to be held on Friday, 24 May 2024 at 10:00 a.m. at 2/F, 35-45B Bonham Strand, Sheung Wan, Hong Kong is set out on pages 21 to 25 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.purapharm.com](http://www.purapharm.com)).

Whether or not you are able to attend the Annual General Meeting, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the Annual General Meeting (i.e. no later than 10:00 a.m. on 22 May 2024) or any adjournment thereof. Completion and return of the form of proxy will not preclude shareholders from attending and voting in person at the Annual General Meeting or any adjournment thereof if they so wish and in such event the proxy form shall be deemed to be revoked.

30 April 2024

---

## CONTENTS

---

	<i>Page</i>
<b>Definitions</b> .....	1
 <b>Letter from the Board</b>	
1. Introduction .....	4
2. Proposed Re-election of Retiring Directors .....	5
3. Proposed Grant of General Mandate to Buy Back Shares .....	6
4. Proposed Grant of General Mandate to Issue New Shares .....	7
5. Proposed Grant of Extension of General Mandate .....	7
6. Re-Appointment of the Auditor .....	7
7. Annual General Meeting and Proxy Arrangement .....	8
8. Closure of Register of Members .....	8
9. Responsibility Statement .....	9
10. General Information .....	9
11. Recommendation .....	9
 <b>Appendix I – Details of the Retiring Directors Proposed to be Re-elected at the Annual General Meeting</b> .....	10
 <b>Appendix II – Explanatory Statement on the Share Buy-back Mandate</b> .....	15
 <b>Notice of Annual General Meeting</b> .....	21

---

## DEFINITIONS

---

*In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:*

“Annual General Meeting”	the annual general meeting of the Company to be held on Friday, 24 May 2024 at 10:00 a.m., at 2/F, 35-45B Bonham Strand, Sheung Wan, Hong Kong to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 21 to 25 of this circular, or any adjournment thereof;
“Articles of Association” or “Articles”	the articles of association of the Company currently in force;
“associate(s)” or “close associate(s)”	having the meaning ascribed to them in the Listing Rules;
“Board”	the board of Directors;
“Companies Act”	The Companies Act of the Cayman Islands, as amended, modified and supplemented from time to time;
“Company”	PuraPharm Corporation Limited, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange;
“Controlling Shareholder(s)”	having the meaning ascribed to it under the Listing Rules, and in the context of this circular, Controlling Shareholders of the Company shall mean Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola;
“connected person(s)”	having the meaning ascribed to them in the Listing Rules;
“Director(s)”	the director(s) of the Company;
“Group”	the Company and its subsidiaries;
“HK\$”	Hong Kong dollar, the lawful currency of Hong Kong;
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China;

---

## DEFINITIONS

---

“Issuance Mandate”	a general mandate proposed to be granted to the Directors to allot, issue or deal with additional Shares of not exceeding 20% of the total number of issued Shares as at the date of passing of the proposed ordinary resolution contained in item 5 of the notice of the Annual General Meeting as set out on pages 21 to 25 of this circular;
“Latest Practicable Date”	22 April 2024, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein;
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange;
“Memorandum and Articles of Association”	the memorandum and articles of association of the Company currently in force;
“Nomination Committee”	the nomination committee of the Company;
“Option(s)”	share option(s) granted under the share option scheme adopted by the Shareholders of the Company on 12 June 2015;
“Remuneration Committee”	the remuneration committee of the Company;
“SFO”	The Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong;
“Share(s)”	ordinary share(s) of US\$0.1 each in the capital of the Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company;
“Share Buy-back Mandate”	a general mandate proposed to be granted to the Directors to buy back Shares on the Stock Exchange, which shall not exceed 10% of the total number of issued Shares as at the date of passing of the proposed ordinary resolution contained in item 4 of the notice of the Annual General Meeting as set out on pages 21 to 25 of this circular;

---

## DEFINITIONS

---

“Share Option Scheme”	the share option scheme approved and adopted by the Shareholders by written resolutions on 12 June 2015;
“Shareholder(s)”	holder(s) of the Share(s);
“Stock Exchange”	The Stock Exchange of Hong Kong Limited;
“Takeovers Code”	the Codes on Takeovers and Mergers and Shares Buy-backs issued by the Securities and Futures Commission in Hong Kong as amended from time to time; and
“%”	per cent.

---

## LETTER FROM THE BOARD

---



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

*Executive Directors:*

Mr. Chan Yu Ling, Abraham (*Chairman*)

Ms. Man Yee Wai, Viola

*Non-executive Director:*

Mr. Leung Stephen Kwok Keung

*Independent non-executive Directors:*

Mr. Ho Kwok Wah, George

Dr. Leung Lim Kin, Simon

Prof. Tsui Lap Chee

*Registered Office:*

P.O. Box 31119

Grand Pavilion Hibiscus Way

802 West Bay Road

Grand Cayman KY1-1205

Cayman Islands

*Headquarter and principal place of  
business in Hong Kong:*

Unit 201–207, 2/F.,

Wireless Centre, Phase One,

Hong Kong Science Park,

Tai Po, New Territories, Hong Kong

30 April 2024

*To the Shareholders*

Dear Sir/Madam,

**(I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;  
(II) PROPOSED GRANT OF GENERAL MANDATES TO BUY BACK SHARES  
AND ISSUE NEW SHARES;  
AND  
(III) NOTICE OF ANNUAL GENERAL MEETING**

**1. INTRODUCTION**

The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the Annual General Meeting for, among other things, (i) the re-election of retiring Directors; and (ii) the grant to the Directors of the Share Buy-back Mandate and the Issuance Mandate.

---

## LETTER FROM THE BOARD

---

### 2. PROPOSED RE-ELECTION OF RETIRING DIRECTORS

In accordance with Article 112 of the Articles of Association, any Director appointed by the Board as an addition to the existing Board shall hold office only until the next following annual general meeting of the Company and shall then be eligible for re-election. As such, Mr. Leung Stephen Kwok Keung shall retire from office at the Annual General Meeting and being eligible, will offer himself for re-election at the Annual General Meeting.

In accordance with Article 108 of the Articles of Association, at each annual general meeting, not less than one-third of the Directors shall be subject to retirement by rotation. As such, Ms. Man Yee Wai, Viola and Prof. Tsui Lap Chee, shall retire from office at the Annual General Meeting. Ms. Man Yee Wai, Viola and Prof. Tsui Lap Chee, being eligible, will offer themselves for re-election at the Annual General Meeting.

Pursuant to the Listing Rules, details of the retiring Directors who offered themselves for re-election, are set out in Appendix I to this circular.

In assessing the suitability of the candidates of Director standing for re-election (including independent non-executive Director), the Nomination Committee shall consider the potential contributions a candidate can bring to the Board in terms of qualifications, skills, experience, independence (where applicable), age, culture, ethnicity and gender diversity. The factors considered by the Nomination Committee in identifying the suitability of a proposed candidate for Director (including independent non-executive Director) include: (i) reputation for integrity; (ii) accomplishment, experience and reputation in the business and industry; (iii) commitment in respect of sufficient time, interest and attention to the businesses of the Group; (iv) compliance with the criteria of independence as prescribed under Rule 3.13 of the Listing Rules (where applicable); and (v) any other relevant factors as may be determined by the Nomination Committee or the Board from time to time as appropriate. The Board shall take into consideration the benefits of a diversified Board when selecting Board candidates.

The nominations were made in accordance with the nomination policy of the Company and the objective criteria (including without limitation, skills, knowledge and experience, and potential time commitment for the board and/or committee responsibilities), with due regard for the benefits of diversity as set out under the board diversity policy of the Company, details of which are set out in the 2023 annual report of the Company. The Nomination Committee had also taken into account the respective contributions of Ms. Man Yee Wai, Viola, Mr. Leung Stephen Kwok Keung and Prof. Tsui Lap Chee to the Board and their commitment to their roles. In particular, Ms. Man Yee Wai, Viola has in-depth knowledge in strategic planning, brand management, consumer and industrial marketing, key account management and new product development, which enable her to provide valuable guidance to the Group's strategy and management. Mr. Leung Stephen Kwok Keung, has extensive experience in the pharmaceutical industry, management and strategic planning, which of particular relevance to the supervision of the Group's performance. Prof. Tsui Lap Chee has extensive experience human genetic disease and genomics research, which enable him to provide valuable insight and independent guidance to the Group's business.

---

## LETTER FROM THE BOARD

---

The Nomination Committee, after considering the diverse educational backgrounds and professional knowledge and experience of Ms. Man Yee Wai, Viola, Mr. Leung Stephen Kwok Keung and Prof. Tsui Lap Chee, was of the view that they will bring valuable perspectives, knowledge, skills and experiences to the Board for its efficient and effective functioning and their appointments will contribute to the diversity of the Board appropriate to the requirements of the Group's business.

The Nomination Committee also assessed and reviewed the annual confirmation of independence based on the independence criteria as set out in Rule 3.13 of the Listing Rules of Prof. Tsui Lap Chee and re-affirmed his independence. The Nomination Committee is also of the view that Prof. Tsui Lap Chee has provided valuable contributions to the Company and has demonstrated his ability to provide independent, balanced and objective views to the Company's matters. As at the Latest Practicable Date, Prof. Tsui Lap Chee did not hold seven or more directorships in listed companies. The Board considers that Prof. Tsui Lap Chee's extensive experience in human genetics and genomics and as a world-renowned scholar will contribute to the diversity of the Board and bring insights from human genetics and genomics prospective to the Board.

The Board accepted the Nomination Committee's nominations and recommended each of Ms. Man Yee Wai, Viola, Mr. Leung Stephen Kwok Keung and Prof. Tsui Lap Chee to stand for re-election as executive Director, non-executive Director and independent non-executive Director at the Annual General Meeting respectively. Prof. Tsui Lap Chee is a member of the Nomination Committee. He abstained from discussion and voting at the Nomination Committee meeting regarding his nomination. Prof. Tsui Lap Chee also abstained from discussion and voting at the Board meeting regarding his nomination.

### **3. PROPOSED GRANT OF GENERAL MANDATE TO BUY BACK SHARES**

In order to give the Company the flexibility to buy back Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the grant of the Share Buy-back Mandate to the Directors to buy back Shares on the Stock Exchange of not exceeding 10% of the total number of issued Shares as at the date of passing of the proposed ordinary resolution contained in item 4 of the notice of the Annual General Meeting as set out on pages 21 to 25 of this circular (i.e. a total of 39,589,727 Shares assuming on the basis that there is no change in the total number of issued Shares of the Company of 395,897,275 Shares between the Latest Practicable Date and the date of the Annual General Meeting). The Directors wish to state that the Board intends to exercise its power under the Share Buy-back Mandate from time to time but have no immediate plan to buy back any Shares pursuant to the Share Buy-back Mandate.



---

## **LETTER FROM THE BOARD**

---

An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the grant of the Share Buy-back Mandate is set out in Appendix II to this circular.

The Share Buy-back Mandate will remain in effect until whichever is the earliest of (i) the conclusion of the next annual general meeting of the Company; or (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable laws to be held; or (iii) the passing of an ordinary resolution of the Shareholders in general meeting revoking or varying the Share Buy-back Mandate.

#### **4. PROPOSED GRANT OF GENERAL MANDATE TO ISSUE NEW SHARES**

In order to give the Company the flexibility to issue Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the grant of the Issuance Mandate to the Directors to allot, issue or deal with additional Shares of not exceeding 20% of the total number of issued Shares as at the date of passing of the proposed ordinary resolution contained in item 5 of the notice of the Annual General Meeting as set out on pages 21 to 25 of this circular (i.e. a total of 79,179,455 Shares assuming on the basis that there is no change in the total number of issued Shares of the Company of 395,897,275 Shares between the Latest Practicable Date and the date of the Annual General Meeting). An ordinary resolution to extend the Issuance Mandate by adding the number of Shares bought back by the Company pursuant to the Share Buy-back Mandate will also be proposed at the Annual General Meeting.

The Directors wish to state that they have no immediate plan to issue any new Shares pursuant to the Issuance Mandate.

The Issuance Mandate will remain in effect until whichever is the earliest of (i) the conclusion of the next annual general meeting of the Company; or (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable laws to be held; or (iii) the passing of an ordinary resolution of the Shareholders in general meeting revoking or varying the Issuance Mandate.

#### **5. PROPOSED GRANT OF EXTENSION OF GENERAL MANDATE**

In addition, if the Share Buy-back Mandate and Issuance Mandate are granted, an ordinary resolution will be proposed at the Annual General Meeting to extend the Issuance Mandate by the addition to the number of the Shares which may be issued, allotted and dealt with or agreed conditionally or unconditionally to be issued, allotted and dealt with by the Directors pursuant to the Issuance Mandate of an amount representing the number of the issued Shares purchased or repurchased by the Company pursuant to the Share Buy-back Mandate.

---

## LETTER FROM THE BOARD

---

### 6. RE-APPOINTMENT OF THE AUDITOR

Ernst & Young will retire as the auditor of the Company at the Annual General Meeting and, being eligible, offer themselves for re-appointment as the auditor of the Company. Details of the re-appointment of auditor are set out in the proposed ordinary resolution contained in item 3 of the notice of the Annual General Meeting.

### 7. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The Company will convene the Annual General Meeting on Friday, 24 May 2024 at 10:00 a.m. at 2/F, 35-45B Bonham Strand, Sheung Wan, Hong Kong.

The notice of the Annual General Meeting is set out on pages 21 to 25 of this circular.

Pursuant to 13.39(4) of the Listing Rules, all votes of the Shareholders at a general meeting must be taken by poll except where the Chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. To the best of the knowledge, information and belief of the Directors, none of the Shareholders is required to abstain from voting on any of the resolutions to be proposed at the Annual General Meeting. An announcement on the poll results will be published by the Company after the Annual General Meeting in the manner prescribed under Rule 13.39(5) of the Listing Rules.

A form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.purapharm.com](http://www.purapharm.com)). The form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power of attorney or authority at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, as soon as possible but in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof. Completion and delivery of the form of proxy will not preclude you from attending and voting at the Annual General Meeting or any adjournment thereof if you so wish and in such event the proxy form shall be deemed to be revoked.

---

## LETTER FROM THE BOARD

---

### 8. CLOSURE OF REGISTER OF MEMBERS

In order to ascertain the entitlement to attend and to vote at the Annual General Meeting, the register of members will be closed from Tuesday, 21 May 2024 to Friday, 24 May 2024 (both dates inclusive), the period during which no transfer of the Shares will be effected. In order to be eligible to attend and vote at the Annual General Meeting, all completed share transfer instruments accompanied by the relevant share certificates shall be lodged with the Company's share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong for registration no later than 4:30 p.m. on Monday, 20 May 2024.

### 9. RESPONSIBILITY STATEMENT

This circular includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors individually and collectively accept full responsibility for the accuracy of the information contained in this circular and confirm, having made all reasonable enquiries that to the best of their knowledge and belief, there are no other facts the omission of which would make any statement in this circular misleading.

### 10. GENERAL INFORMATION

Your attention is drawn to the additional information set out in Appendix I (Details of the Retiring Directors Proposed to be Re-elected at the Annual General Meeting) and Appendix II (Explanatory Statement on the Share Buy-back Mandate) to this circular.

### 11. RECOMMENDATION

The Directors consider that all resolutions to be proposed at the Annual General Meeting are in the best interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

Yours faithfully,  
For and on behalf of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

---

## APPENDIX I DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING

---

*The following are details of the Directors who will retire and being eligible, offer themselves for re-election at the Annual General Meeting.*

### **Executive Director**

**Ms. Man Yee Wai, Viola (文綺慧)**, aged 58, is an Executive Director and has been with the Group since its founding in 1998. She is responsible for corporate and brand strategies, and the overall strategic planning of the Group's business. Ms. Man was the Key Account Manager and Group Product Manager of Nestle China Limited and the Consumer Marketing Manager of Coca-Cola China Ltd. and has over 20 years of experience in strategic planning, brand management, consumer and industrial marketing, key account management and new product development. Ms. Man was the Chairman (2012/13) of Tung Wah Group of Hospitals ("TWGHs"), one of the largest charitable organisations principally engaged in the provision of medical and health services, education and community services in Hong Kong and was a member of the Advisory Board of TWGHs (2013/14). Ms. Man was the Founding Chairman of the Board of Governors and College Council of Tung Wah College, and is the Council Chairman of Tung Wah College from 2010-2023. She is a co-opted member of Community Care Fund Task Force of the Commission on Poverty and a fellow of Hong Kong Institute of Directors. She is a member of the HK Constitution and Basic Law Promotion Steering Committee (2017-2023), an appointed member of the Board of Stewards of the Education University of Hong Kong (2015-2024), a member of the Council of the Education University of Hong Kong (2013-2019) and a member of the Betting and Lotteries Commission (2013-2019). Ms. Man was a member of the Advisory Committee of the School of Chinese Medicine of Hong Kong Baptist University (2010 to 2016), and a member of the Risk Communication Advisory Group of the Centre for Health Protection of the Health Department (2013 to 2016). Ms. Man is a member of the 11th and 12th Chinese People's Political Consultative Conference of Sichuan Province. She was awarded the Bronze Bauhinia Star by the Chief Executive of Hong Kong SAR in 2013. Ms. Man obtained her Bachelor's Degree in Science from The University of Western Ontario, Canada and her Master's Degree in Business Administration from The University of Windsor in Canada. She is the spouse of Mr. Chan Yu Ling, Abraham, the Group's Chairman, Chief Executive Officer and Executive Director.

Save as disclosed above, Ms. Man did not hold any directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years and does not have relationships with other directors, senior management or substantial or controlling shareholders of the Company.

---

## APPENDIX I DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING

---

Ms. Man has entered into a service contract with the Company for a fixed term of three years commencing on 8 July 2018, unless terminated by either Ms. Man or the Company in accordance with the terms of the service contract and she is subject to retirement by rotation and is eligible for re-election at least once every three years at the annual general meeting of the Company in accordance with Article 108 of the Articles of Association.

Ms. Man is entitled to receive director's remuneration in the amount of HK\$1,362,000 per annum. Ms. Man's remuneration has been determined by the Board based on the recommendation of the Remuneration Committee and with reference to the prevailing market practice, the Company's remuneration policy and Ms. Man's duties and responsibilities with the Company as well as her performance.

As at the Latest Practicable Date, Ms. Man was interested in 227,119,147 Shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save for the information disclosed above, there is no information which is discloseable nor is Ms. Man involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Ms. Man that need to be brought to the attention of the Shareholders.

### Non-executive Director

**Mr. Leung Stephen Kwok Keung (梁國強)**, aged 68, has over 35 years of extensive experience in management, marketing and strategic planning.

Mr. Leung started his distinguished career at Pfizer Hong Kong, the country office of Pfizer Inc. ("Pfizer") as a sales representative in 1983 and was transferred to Pfizer Australia as a product manager in 1986. In 1991, he was promoted to the Pfizer's New York Headquarters as an international marketing manager. In 1994, Mr. Leung was transferred back to Pfizer Australia as a sales manager and then disease management manager before returning to Hong Kong as a country manager of Pfizer Hong Kong in 1997. Mr. Leung then retired from Pfizer in March 2022 and under his leadership, Pfizer Hong Kong has won the prestigious HKMA Quality Gold Award, Outstanding Corporate Citizenship Gold Award and Best Companies to Work for in Asia.

---

## **APPENDIX I   DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING**

---

Over the decades, Mr. Leung has been actively serving the Hong Kong community in various capacities including (i) the chairman of School of Pharmacy Advisory Board and member of Consultative Committee of the School of Nursing in The Chinese University of Hong Kong; (ii) member of the Incorporated Management Committee in The Hong Kong Management Association K S Lo College; (iii) council members of various associations including The Hong Kong Management Association (the “**HKMA**”), Hong Kong College of Health Service Executives (“**HKCHSE**”), College of Pharmacy Practice (“**CPP**”) and the Common Purpose Hong Kong; and (iv) ex-member of each of the Advisory Council on Food and Environmental Hygiene and Council on Human Reproductive Technology in Hong Kong. Mr. Leung is also a Fellow of each of the HKMA, HKCHSE, CPP and The Australasian College of Health Service Management.

Mr. Leung was honoured with the Asia Coaching Leadership Excellence Award in 2015, the Leader of the Year Award in 2016 and the Exemplary Leader Award in 2021, recognizing his visionary leadership and unremitting contribution to the industry. Mr. Leung received a bachelor’s degree in pharmacy from John Moore University in the United Kingdom and a master’s degree in business (marketing) from The University of Manchester Institute of Science and Technology in the United Kingdom in 1979 and 1982 respectively. He is also a registered pharmacist in Hong Kong and the United Kingdom as well as a certified executive coach with The Worldwide Association of Business Coaches and International Coaching Federation.

Save as disclosed above, Mr. Leung did not hold any directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years and does not have relationships with other directors, senior management or substantial or controlling shareholders of the Company.

Mr. Leung has entered into a letter of appointment with the Company for a term of three years commencing on 14 June 2023, unless terminated by either Mr. Leung or the Company in accordance with the terms of the letter of appointment and he is subject to retirement by rotation and is eligible for re-election at least once every three years at the annual general meeting of the Company in accordance with Article 108 of the Articles of Association.

Mr. Leung is entitled to receive director’s remuneration in the amount of HK\$200,000 per annum. Mr. Leung’s remuneration has been determined by the Board based on the recommendation of the Remuneration Committee and with reference to the prevailing market practice, the Company’s remuneration policy and Mr. Leung’s duties and responsibilities with the Company as well as his performance.

---

## APPENDIX I DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING

---

As at the Latest Practicable Date, Mr. Leung does not hold any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save for the information disclosed above, there is no information which is discloseable nor is Mr. Leung involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. Leung that need to be brought to the attention of the Shareholders.

### **Independent Non-executive Director**

**Prof. Tsui Lap Chee (徐立之)**, aged 73, is an Independent Non-executive Director. He is University Professor Emeritus at University of Toronto, Ontario, Canada. He is also an Independent Non-Executive Director of Hang Lung Group Limited (stock code: 0010). Prior to joining the Purapharm Group, he was the Vice Chancellor of the University of Hong Kong. Prof. Tsui has over 40 years of experience in human genetic disease and genomics research, reflected in his over 300 peer-reviewed scientific publications and 65 invited book chapters. He was the recipient of many national and international prizes, as well as 16 honorary doctoral degrees from universities around the world. He was appointed as the Justice of the Peace in 2006 and awarded the Gold Bauhinia Star and the Grand Bauhinia Medal by the Chief Executive of Hong Kong SAR in 2011 and 2016, respectively. He received a Doctor of Philosophy Degree from University of Pittsburgh in the U.S.A.

Save as disclosed above, Prof. Tsui did not hold any directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years and does not have relationships with other directors, senior management or substantial or controlling shareholders of the Company.

Prof. Tsui has signed a letter of appointment with the Company regarding his appointment as independent non-executive Director commencing on 8 July 2021 for a fixed term of three years, unless terminated by either Prof. Tsui or the Company in accordance with the terms of the letter of appointment and he is subject to retirement by rotation and is eligible for reelection at least once every three years at the annual general meeting of the Company in accordance with Article 108 of the Articles of Association.

Prof. Tsui is not entitled to receive salary but is entitled to receive director's fee in the amount of HK\$200,000 per annum. Prof. Tsui's remuneration has been determined by the Board based on the recommendation of the Remuneration Committee and with reference to the prevailing market practice, the Company's remuneration policy and Prof. Tsui's duties and responsibilities with the Company as well as his performance.

---

**APPENDIX I    DETAILS OF THE RETIRING DIRECTORS PROPOSED TO  
BE RE-ELECTED AT THE ANNUAL GENERAL MEETING**

---

As at the Latest Practicable Date, Prof. Tsui was beneficially interested in 20,000 shares of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Prof. Tsui involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Prof. Tsui that need to be brought to the attention of the Shareholders.



*This Appendix is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the Annual General Meeting in relation to the grant of the Share Buy-back Mandate.*

### **1. SHARES IN ISSUE**

As at the Latest Practicable Date, the total number of issued Shares of the Company comprised 395,897,275 Shares in one class.

Subject to the passing of the ordinary resolution set out in item 4 of the notice of the Annual General Meeting in respect of the grant of the Share Buy-back Mandate and on the basis that there will be no change to the total number of issued Shares of the Company before the Annual General Meeting, i.e. being 395,897,275 Shares, the Directors would be authorised under the Share Buy-back Mandate to buy back, during the period in which the Share Buy-back Mandate remains in force, a total of 39,589,727 Shares, representing 10% of the total number of Shares in issue as at the date of the Annual General Meeting.

### **2. REASONS FOR SHARE BUYBACK**

The Directors believe that the granting of the Share Buy-back Mandate is in the best interests of the Company and the Shareholders.

Shares buybacks may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such a buyback will benefit the Company and the Shareholders.

### **3. FUNDING OF BUYBACK**

In buying-back Shares, the Company may only apply the Company's available cash flow or working capital facilities which will be funds legally available for such purpose in accordance with its Memorandum and Articles of Association, the laws of the Cayman Islands and/or any other applicable laws, as the case may be.

The Directors propose that the buyback of Shares under the proposed Share Buy-back Mandate would be financed from the Company's internal resources.

**4. IMPACT OF BUYBACK**

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited financial statements contained in the annual report of the Company for the year ended 31 December 2023) in the event that the Share Buy-back Mandate was to be carried out in full at any time during the proposed buyback period.

However, the Directors do not intend to exercise the Share Buy-back Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

**5. MARKET PRICES OF SHARES**

The highest and lowest prices per Share at which Shares have traded on the Stock Exchange in each of the previous twelve months were as follows:

	<b>Month</b>	<b>Highest HK\$</b>	<b>Lowest HK\$</b>
2023	April	1.19	1.01
	May	1.08	0.96
	June	1.05	0.91
	July	1.07	0.90
	August	1.00	0.82
	September	1.26	0.90
	October	1.22	0.98
	November	1.09	0.94
	December	0.99	0.86
2024	January	0.95	0.74
	February	0.86	0.75
	March	0.90	0.75
	April (up to the Latest Practicable Date)	0.89	0.73

**6. GENERAL**

To the best of the knowledge of the Directors and having made all reasonable enquiries, none of the Directors nor any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company in the event that the grant of the Share Buy-back Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any Shares to the Company, or that they have undertaken not to sell any Shares held by them to the Company in the event that the grant of the Share Buy-back Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to make buyback of Shares pursuant to the Share Buy-back Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands. Neither this explanatory statement nor the proposed buyback of Shares to be conducted under the Share Buy-back Mandate has any unusual features.

**7. TAKEOVERS CODE AND PUBLIC FLOAT REQUIREMENT**

If as a result of a Shares buyback pursuant to the Share Buy-back Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

**APPENDIX II****EXPLANATORY STATEMENT ON  
THE SHARE BUY-BACK MANDATE**

To the best knowledge of the Company, as at the Latest Practicable Date, according to the register of interests kept by the Company pursuant to section 336 of the SFO and so far as is known to, or can be ascertained after reasonable enquiry by the Directors, the following Shareholders were directly or indirectly interested in 5% or more of the issued Shares:

<b>Name of Shareholders</b>	<b>Nature of Interest</b>	<b>Number of Shares held or interested<sup>(1)</sup></b>	<b>Percentage of the Company's issued share capital</b>
Mr. Chan Yu Ling, Abraham ("Mr Abraham Chan")	Interest of controlled corporations	178,854,830 (L) <sup>(2)(3)(4)</sup>	45.18%
	Beneficial owner	40,008,267 (L)	10.11%
	Interest of spouse	8,226,050 (L) <sup>(5)</sup>	2.08%
	Beneficiary of a trust	30,000 (L) <sup>(9)</sup>	0.008%
Ms. Man Yee Wai, Viola ("Ms. Viola Man")	Interest of a controlled corporation	77,349,750 (L) <sup>(6)</sup>	19.54%
	Beneficial owner	8,211,050 (L)	2.07%
	Interest of spouse	141,543,347 (L) <sup>(7)</sup>	35.75%
	Beneficiary of a trust	15,000 (L) <sup>(9)</sup>	0.004%
PuraPharm Corporation Limited ("PuraPharm Corp")	Beneficial owner	77,349,750 (L) <sup>(2)</sup>	19.54%
Joint Partners Investment Limited ("Joint Partners")	Interest of a controlled corporation	77,349,750 (L) <sup>(8)</sup>	19.54%
Fullgold Development Limited ("Fullgold Development")	Beneficial owner	81,929,000 (L)	20.69%
Gold Sparkle Limited ("Gold Sparkle")	Beneficial owner	19,576,080 (L)	4.94%

*Notes:*

- (1) The letter "L" denotes the person's long position in such securities.
- (2) Mr. Abraham Chan beneficially owns the 50% of the issued share capital of Joint Partners, which in turn wholly owns the issued capital of PuraPharm Corp, a limited liability company incorporated in the British Virgin Islands on 5 May 1998. PuraPharm Corp owns 77,349,750 Shares. By virtue of the SFO, Mr. Abraham Chan is deemed to be interested in the Shares held by PuraPharm Corp.

---

**APPENDIX II****EXPLANATORY STATEMENT ON  
THE SHARE BUY-BACK MANDATE**

---

- (3) Mr. Abraham Chan wholly owns the issued share capital of Fullgold Development, which in turn owns 81,929,000 Shares. By virtue of the SFO, Mr. Abraham Chan is deemed to be interested in the Shares held by Fullgold Development.
- (4) Mr. Abraham Chan beneficially owns the entire issued share capital of Gold Sparkle, which in turn owns 19,576,080 Shares. By virtue of the SFO, Mr. Abraham Chan is deemed to be interested in the Shares held by Gold Sparkle.
- (5) Mr. Abraham Chan is the spouse of Ms. Viola Man. By virtue of the SFO, Mr. Abraham Chan is deemed to be interested in the Shares held by Ms. Viola Man.
- (6) Ms. Viola Man beneficially owns the 50% of the issued share capital of Joint Partners, which in turn wholly owns the issued capital of PuraPharm Corp. PuraPharm Corp owns 77,349,750 Shares. By virtue of the SFO, Ms. Viola Man is deemed to be interested in the Shares held by PuraPharm Corp.
- (7) Ms. Viola Man is the spouse of Mr. Abraham Chan. By virtue of the SFO, Ms. Viola Man is deemed to be interested in the Shares held by Mr. Abraham Chan.
- (8) PuraPharm Corp is wholly owned by Joint Partners. By virtue of the SFO, Joint Partners is deemed to be interested in the Shares held by PuraPharm Corp.
- (9) These Shares represent Shares granted to Mr. Abraham Chan and Ms. Viola Man pursuant to a share award scheme adopted by the Company on 22 February 2016 (the “Share Award Scheme”), which are held on trust by a trust set up by the Company for the purpose of administering the Share Award Scheme Trust until the Shares are vested.

Assuming that there is no change in the number of Shares between the Latest Practicable Date and the date of a buyback under the proposed Share Buy-back Mandate, in the event that the Directors exercise the power to buy back Shares in full in accordance with the proposed Share Buy-back Mandate, the aggregate shareholding of the above Shareholders in the issued share capital of the Company would be increased to:

<b>Name of Shareholders</b>	<b>Nature of Interest</b>	<b>Percentage of the Company’s issued share capital</b>
Mr. Abraham Chan	Interest of controlled corporations	50.20%
	Beneficial owner	11.23%
	Interest of spouse	2.31%
	Beneficiary of a trust	0.008%

<b>Name of Shareholders</b>	<b>Nature of Interest</b>	<b>Percentage of the Company's issued share capital</b>
Ms. Viola Man	Interest of a controlled corporation	21.71%
	Beneficial owner	2.30%
	Interest of spouse	39.73%
	Beneficiary of a trust	0.004%
PuraPharm Corp	Beneficial owner	21.71%
Joint Partners	Interest of a controlled corporation	21.71%
Fullgold Development	Beneficial owner	22.99%
Gold Sparkle	Beneficial owner	5.49%

The Directors are not aware of the consequences of such increases or as a result of the buyback of Shares that would result in any of the aforesaid Shareholders or any Shareholder, or group of Shareholders acting in concert, becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code. Moreover, the Directors do not propose to exercise the Share Buy-back Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code and/or result in the aggregate number of Shares held by the public shareholders falling below 25%, the prescribed minimum percentage required by the Stock Exchange.

#### **8. BUYBACK OF SHARES MADE BY THE COMPANY**

During the 12 months prior to the Latest Practicable Date, the Company had not bought back any of the Shares (whether on the Stock Exchange or otherwise).

---

## NOTICE OF ANNUAL GENERAL MEETING

---



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

### NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that an Annual General Meeting of PuraPharm Corporation Limited (the “**Company**”) will be held on Friday, 24 May 2024 at 10:00 a.m. at 2/F, 35-45B Bonham Strand, Sheung Wan, Hong Kong, for the following purposes:

#### ORDINARY RESOLUTIONS

To consider and, if thought fit, pass the following resolutions (with or without modifications) as ordinary resolutions of the Company:

1. To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “**Directors**”) and the auditor of the Company for the year ended 31 December 2023.
2.
  - (a) To re-elect Ms. Man Yee Wai, Viola as an Executive Director.
  - (b) To re-elect Mr. Leung Stephen Kwok Keung as a Non-executive Director.
  - (c) To re-elect Prof. Tsui Lap Chee as an Independent non-executive Director.
  - (d) To authorise the board of Directors to fix the Directors’ remuneration.
3. To re-appoint Ernst & Young as auditor of the Company to hold office until conclusion of the next annual general meeting and to authorise the board of Directors to fix the auditor’s remuneration.

---

## NOTICE OF ANNUAL GENERAL MEETING

---

4. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT:**

- (a) subject to paragraph 4(b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to exercise during the Relevant Period (as defined below) all the powers of the Company to buy back shares of the Company in accordance with all applicable laws, rules and regulations;
- (b) the total number of shares of the Company to be bought back pursuant to the mandate in paragraph 4(a) above shall not exceed 10% of the total number of issued shares of the Company as at the date of passing of this resolution and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be bought back under the mandate in paragraph 4(a) above as a percentage of the total number of issued shares at the date immediately before and after such consolidation or subdivision shall be the same; and
- (c) for the purposes of this resolution:

“Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and
- (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting.”



---

## NOTICE OF ANNUAL GENERAL MEETING

---

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT:**

- (a) subject to paragraph 5(c) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company during the Relevant Period (as defined below) to allot, issue and deal with additional shares in the capital of the Company and to make or grant offers, agreements and options which might require the exercise of such powers;
- (b) the mandate in paragraph 5(a) above shall authorise the directors of the Company to make or grant offers, agreements and options during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;
- (c) the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted by the directors pursuant to the mandate in paragraph 5(a) above, otherwise than pursuant to:
  - (i) a Rights Issue (as defined below);
  - (ii) the exercise of options under a share option scheme of the Company; and
  - (iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company,

shall not exceed 20% of the total number of issued shares of the Company as at the date of passing of this resolution and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be issued under the mandate in paragraph 5(a) above as a percentage of the total number of issued shares at the date immediately before and after such consolidation or subdivision shall be the same; and

---

## NOTICE OF ANNUAL GENERAL MEETING

---

(d) for the purposes of this resolution:

“Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and
- (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting.

“Right Issue” means an offer of shares open for a period fixed by the directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognised regulatory body or any stock exchange).”

6. As special business, to consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT** conditional upon the passing of the resolutions set out in items 4 and 5 of the notice convening this meeting (the “**Notice**”), the general mandate referred to in the resolution set out in item 5 of the Notice be and is hereby extended by the addition to the aggregate number of shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the directors pursuant to such general mandate of the number of shares bought back by the Company pursuant to the mandate referred to in resolution set out in item 4 of the Notice, provided that such amount shall not exceed 10% of the total number of issued share of the Company as at the date of the passing of this resolution.”

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 30 April 2024

---

## NOTICE OF ANNUAL GENERAL MEETING

---

*Notes:*

1. All resolutions at the meeting will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) except where the Chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
2. Any shareholder of the Company entitled to attend and vote at the above meeting is entitled to appoint another person as his proxy to attend and vote instead of him. A shareholder who is the holder of two or more shares may appoint more than one proxy to represent him and vote on his behalf at the above meeting. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy.
3. The form of proxy together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of that power of attorney or authority, must be deposited at the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong not less than 48 hours before the time appointed for the holding of the meeting or any adjournment thereof. Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the Annual General Meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. For determining the entitlement to attend and vote at the above meeting, the register of members of the Company will be closed from Tuesday, 21 May 2024 to Friday, 24 May 2024, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong for registration not later than 4:30 p.m. on Monday, 20 May 2024.
5. A circular containing further details concerning items 2, 4, 5, and 6 set out in the above notice will be sent to all shareholders of the Company together with the annual report of the Company for the year ended 31 December 2023.
6. The translation into Chinese language of this notice is for reference only. In case of any inconsistency, the English version shall prevail.

*As at the date of this notice, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*